middle.news

Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global Approvals

7:00am on Thursday 18th of December, 2025 AEDT • Healthcare
Read Story

Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global Approvals

7:00am on Thursday 18th of December, 2025 AEDT
Key Points
  • Part 1 enrolment for ProstACT Phase 3 study completed
  • Independent Data Monitoring Committee endorses trial progression
  • Part 2 initiated with first patients dosed in Australia, New Zealand, and Canada
  • Regulatory approvals obtained in China, Singapore, Türkiye, UK, South Korea, and Japan
 Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE